PNC Financial Services Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,962 shares of the biopharmaceutical company's stock after selling 755 shares during the period. PNC Financial Services Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $10,124,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of REGN. Adirondack Trust Co. boosted its position in shares of Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 18 shares during the period. Kingswood Wealth Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after buying an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its holdings in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after buying an additional 19 shares during the period. Private Trust Co. NA increased its stake in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 19 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after buying an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ:REGN traded down $14.77 during midday trading on Wednesday, hitting $555.13. The company's stock had a trading volume of 864,754 shares, compared to its average volume of 969,242. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.73 and a current ratio of 4.60. The business's 50 day simple moving average is $537.05 and its 200 day simple moving average is $601.77. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a market cap of $59.93 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company's revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.56 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the stock. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Citigroup restated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $841.30.
Check Out Our Latest Research Report on REGN
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.